
CGEM
Cullinan Therapeutics Inc.
$7.54
-$0.07(-0.92%)
20
Overall
--
Value
10
Tech
31
Quality
Market Cap
$451.33M
Volume
285.36K
52W Range
$6.85 - $19.89
Target Price
$26.88
Order:
Income Statement
Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|
REVENUE | ||||||
Total Revenue | $18.9M | $100.0K | $500.0K | -- | ||
Total Revenue | $18.9M | $100.0K | $500.0K | -- | ||
GROSS PROFIT | ||||||
Gross Profit | $18.9M | $100.0K | $500.0K | -- | ||
OPERATING EXPENSES | ||||||
Operating Expenses | $86.9M | $132.1M | $190.6M | $196.9M | ||
Research & Development | $57.8M | $91.9M | $148.2M | $142.9M | ||
Research Expense | $57.8M | $91.9M | $148.2M | $142.9M | ||
Selling, General & Administrative | $29.1M | $40.2M | $42.5M | $54.0M | ||
General & Administrative Expenses | $29.1M | $40.2M | $42.5M | $54.0M | ||
Salaries & Wages | $24.4M | $28.0M | $30.4M | $37.8M | ||
Depreciation & Amortization | $100.0K | $100.0K | $300.0K | $300.0K | ||
Depreciation & Amortization | $100.0K | $100.0K | $300.0K | $300.0K | ||
Other Operating Expenses | -- | -- | $1.7M | -- | ||
OPERATING INCOME | ||||||
Operating income | $-68.0M | $144.6M | $-191.1M | $-196.9M | ||
EBITDA | $-64.3M | $-132.0M | $-179.1M | $-182.6M | ||
NON-OPERATING ITEMS | ||||||
Intinc | $477.0K | $6.6M | $21.6M | $29.7M | ||
Net Non-Operating Interest Income/Expense | $477.0K | $6.6M | $21.6M | $29.7M | ||
Other Income/Expense | $8.0K | $276.8M | $-239.0K | $199.0K | ||
Other Special Charges | $-8.0K | $57.0K | $239.0K | $-199.0K | ||
SPECIAL ITEMS | ||||||
Other Impairment Of Capital Assets | -- | -- | $440.0K | -- | ||
PRE-TAX INCOME | ||||||
EBIT | $-67.5M | $-132.1M | $-169.2M | $-167.5M | ||
Pre-Tax Income | $-67.5M | $151.3M | $-169.2M | $-167.5M | ||
INCOME TAX | ||||||
Tax Provision | -- | $42.1M | $-14.1M | $117.0K | ||
NET INCOME | ||||||
Net Income | $-65.6M | $111.2M | $-153.2M | $-167.4M | ||
Net Income (Continuing Operations) | $-65.6M | $109.2M | $-155.1M | $-167.6M | ||
Net Income (Discontinued Operations) | $-65.6M | $111.2M | $-153.2M | $-167.4M | ||
Net Income (Common Stockholders) | $-65.6M | $111.2M | $-153.2M | $-167.4M | ||
Normalized Income | $-53.3M | -- | -- | $-165.8M | ||
TOTALS | ||||||
Total Expenses | $86.9M | $132.1M | $190.6M | $196.9M | ||
SHARE & EPS DATA | ||||||
Average Shares Outstanding | $43.1M | $45.2M | $41.5M | -- | ||
Average Shares Outstanding (Diluted) | -- | $46.6M | $41.5M | -- | ||
Shares Outstanding | $44.6M | $39.3M | $43.1M | $58.5M | ||
Basic EPS | $-1.52 | $2.46 | $-3.69 | -- | ||
Basic EPS (Continuing Operations) | $-1.52 | $2.46 | $-3.69 | -- | ||
Diluted EPS | $-1.52 | $2.38 | $-3.69 | -- | ||
Diluted EPS (Continuing Operations) | -- | $2.38 | $-3.69 | -- | ||
OTHER METRICS | ||||||
Minority Interests | $1.9M | $2.0M | $1.9M | $192.0K | ||
Other Gand A | $29.1M | $40.2M | $42.5M | $54.0M |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | CGEM | $7.54 | -0.9% | 285.36K |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Cullinan Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW